Now ketamine, a glutamatergic NMDA receptor antagonist, may provide a mechanism that could link these pathways. Figure 1: A schematic of how ketamine may lead to an overall excitation in the cortex.

The use of combination therapy with a cholinomimetic (AChEI) and a glutamatergic (memantine) agent for the treatment of AD is justified by findings from biochemical studies, and preclinical ...

The group focuses on studying the mechanisms guiding activity-dependent development of glutamatergic circuitry in the limbic system and in particular, the roles of ionotropic glutamate receptors in ...

With regard to understanding the disease process in AD, it is of considerable interest to consider the temporal relationship between the loss of cholinergic and glutamatergic neurons. Biochemical ...

Glutamatergic medications showed promise in treating obsessive-compulsive and related disorders (OCRDs), especially obsessive-compulsive disorder (OCD), a systematic review and meta-analysis ...